SCHEMBL5830734

SCHEMBL5830734

Cc1cc(-c2nsc(NS(=O)(=O)c3cccc(Cl)c3C)n2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.46
KDM1A O60341 2/20 0.43
MAOA P21397 2/20 0.43
SLC40A1 Q9NP59 1/20 0.42
EDNRB P24530 2/20 0.42
EDNRA P25101 2/20 0.42
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
CCR4 P51679 1/20 0.40
FSCN1 Q16658 1/20 0.39
ACLY P53396 1/20 0.39
TASP1 Q9H6P5 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
SCN1A P35498 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN8A Q9UQD0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5390844 0.84 HSD11B1 (0.56) HSD11B1KDM1AMAOASLC40A1EDNRB
SCHEMBL2763006 0.82 KDM1A (0.61) HSD11B1KDM1AMAOAHSD17B1HSD17B2
SCHEMBL6695994 0.81 HSD11B1 (0.35) HSD11B1KDM1AMAOAHSD17B1HSD17B2
SCHEMBL5830969 0.81 KDM1A (0.52) HSD11B1KDM1ASLC40A1EDNRBEDNRA
SCHEMBL5398218 0.80 HSD11B1 (0.48) HSD11B1KDM1AMAOASLC40A1EDNRB
SCHEMBL5831629 0.79 HSD11B1 (0.52) HSD11B1KDM1AMAOASLC40A1EDNRB
SCHEMBL5395063 0.79 HSD11B1 (0.50) HSD11B1KDM1AMAOASLC40A1EDNRB
SCHEMBL5401636 0.78 HSD11B1 (0.58) HSD11B1KDM1AMAOASLC40A1EDNRB
SCHEMBL6690238 0.77 SLC40A1 (0.46) HSD11B1SLC40A1EDNRBEDNRAACLY
SCHEMBL5398850 0.77 HSD11B1 (0.49) HSD11B1KDM1AMAOASLC40A1EDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885KDM1A 1842/4885MAOA 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.